Davis Capital Management’s Vir Biotechnology VIR Stock Holding History

Davis Capital Management’s Portfolio VIR Stock Details VIR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$61	Buy	+6	New	+$57	﹤0.01%	1171

Other funds holding VIR

Alta Partners Management Company Jackson, Wyoming $127M AUM 230.85% 1-Year Est. Return

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS)

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return

Caisse Des Depots Et Consignations Paris, France $5.91B AUM 35.65% 1-Year Est. Return

State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return

Amalgamated Bank New York $14.5B AUM 44.3% 1-Year Est. Return

Diversified Trust Memphis, Tennessee $6.24B AUM 28.78% 1-Year Est. Return

Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return

Davis Capital Management's VIR Position: Q2 2026 in Review

Davis Capital Management opened a new position in Vir Biotechnology (VIR) in Q2 2026: 6 shares worth $61. The stake represents ﹤0.01% of the portfolio and ranks #1171 among its holdings.

31 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

Davis Capital Management held 6 shares of Vir Biotechnology worth $61 as of Q2 2026.
Vir Biotechnology was a new Davis Capital Management position in Q2 2026.
Vir Biotechnology made up ﹤0.01% of Davis Capital Management's portfolio in Q2 2026, its #1171 holding.
31 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on Davis Capital Management's 13F filing for Q2 2026, filed 16 Jul 2026.